Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Daniel Slade, MSc, BSc (Hons), Jenny Byrne, MD PhD, Kristian Brock, MSc, BSc, Hugues De Lavallade, Charles Craddock, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD, Matthew Smith, MBBS, Rebecca Bishop, BSc, Dragana Milojkovic, MBBS, MD, Christina Yap, MSci, PhD CStat

Blood (2019) 134 (Supplement_1): 497.

https://doi.org/10.1182/blood-2019-125591

Published: 2019

Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD

Blood (2017) 130 (Supplement 1): 1554.

https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554

Published: 2017

Journal Articles

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Ellen K. Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Michael W Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ghulam Warsi, PhD, Carole S. Paley, Ilva Dautaj, Felice P. Lin, PharmD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4050.

https://doi.org/10.1182/blood.V126.23.4050.4050

Published: 2015

Journal Articles

Amylase-Producing Myeloma Cells Reduced Sensitivity to Dexamethasone and Bortezomib.

Shohei Mizuno, MD, Ichiro Hanamura, MD PhD, Akinobu Ota, Karnan Sivasundaram, Tomoko Narita, MD, Masaki Ri, MD PhD, Motonori Mizutani, MD, Mineaki Goto, MD PhD, Mayuko Gotou, MD PhD, Norikazu Tsunekawa, MD PhD, Masato Shikami, MD PhD, Shinsuke Iida, Yoshitaka Hosokawa, MD PhD, Hiroshi Miwa, MD PhD, Ryuzo Ueda, MD PhD, Masakazu Nitta, MD PhD, Akiyoshi Takami, MD PhD

Blood (2014) 124 (21): 5690.

https://doi.org/10.1182/blood.V124.21.5690.5690

Published: 2014

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Noopur Raje, MD, Dan T. Vogl, MD, MSCE, Parameswaran N. Hari, MD, MRCP, MS, Sundar Jagannath, MD, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, M.D., Ph.D., Paul G. Richardson, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 759.

https://doi.org/10.1182/blood.V122.21.759.759

Published: 2013

Journal Articles

Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jorge E. Cortes, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintas-Cardama, MD, Farhad Ravandi, MD, Evguenia Gachimova, Zeev Estrov, MD, Elias Jabbour, MD, Susan O'Brien, MD, Hagop Kantarjian, MD

Blood (2013) 122 (21): 1483.

https://doi.org/10.1182/blood.V122.21.1483.1483

Published: 2013

Journal Articles

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Tapan M. Kadia, MD, Jorge E. Cortes, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintás-Cardama, MD, Melanie Baccus, RN, Rebecca Garris, BSc, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2012) 120 (21): 4308.

https://doi.org/10.1182/blood.V120.21.4308.4308

Published: 2012

Journal Articles

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Noopur Raje, MD, Parameswaran N Hari, MD, MRCP, MS, Dan T. Vogl, MD, MSCE, Sundar Jagannath, MD, Robert Z. Orlowski, M.D., Ph.D., Jeffrey G Supko, PhD, Patricia Stephenson, ScD, Simon S Jones, Catherine Wheeler, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 4061.

https://doi.org/10.1182/blood.V120.21.4061.4061

Published: 2012

Journal Articles

L-Asparaginase Monotherapy in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of A Phase II Study.

Ye Guo, Xuejun Ma, Zuguang Xia, Kai Xue, Qunling Zhang, Xiaonan Hong

Blood (2012) 120 (21): 2730.

https://doi.org/10.1182/blood.V120.21.2730.2730

Published: 2012

Journal Articles

Phase I Study of Clofarabine (JC0707) in Adult Japanese Patients with Acute Myeloid Leukemia (AML)

Takahiro Yamauchi, MD, PhD, Tatsuya Suzuki, MD, PhD, Kiyoshi Ando, MD, PhD, Tadashi Nagai, MD, PhD, Kazuhiko Kakihana, MD, PhD, Yasuhiko Miyata, MD, PhD, Reginald Ewesuedo, MD, Yasuhiro Tabata, MD, PhD, Michinori Ogura

Blood (2011) 118 (21): 4295.

https://doi.org/10.1182/blood.V118.21.4295.4295

Published: 2011

Journal Articles

Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.

Maya Koren-Michowitz, MD, Philipp D. le Coutre, MD, Justus Duyster, MD, Christof Scheid, Panayiotis Panayiotidis, Witold Prejzner, MD, Jacob M. Rowe, MD, Michaela Schwarz, Neta Goldschmidt, MD, Arnon Nagler, MD

Blood (2009) 114 (22): 3297.

https://doi.org/10.1182/blood.V114.22.3297.3297

Published: 2009

Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 1115.

https://doi.org/10.1182/blood.V114.22.1115.1115

Published: 2009

Journal Articles

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Lubomir Sokol, MD, PhD, Larry Cripe, M.D., Hagop Kantarjian, M.D., Mikkael A. Sekeres, M.D., Simrit Parmar, M.D., Peter Greenberg, M.D., Stuart Goldberg, M.D., Vikas Bhushan, M.D., Jamile Shammo, M.D., Raymond Hohl, M.D., Ph.D., Yu-Ping Li, Ph.D., Ann Lowe, M.D., Joy Zhu, M.D., Alan List, M.D.

Blood (2006) 108 (11): 2657.

https://doi.org/10.1182/blood.V108.11.2657.2657

Published: 2006

Journal Articles

Keratinocyte Growth Factor Factor (Palifermin) in Combination with Tacrolimus and Methotrexate for the Prevention of Acute Graft-Vs-Host Disease (aGVHD) in Patients at High Risk of Agvhd.

Christopher M. Reynolds, MD, John E. Levine, MD, Joseph P. Uberti, MD, Voravit Ratanatharathorn, MD, Lois J. Ayash, MD, Samuel M. Silver, MD, Gregory A. Yanik, MD, Pavan R. Reddy, MD, Cooke R. Kenneth, MD, Becker W. Michael, MD, Hutchinson J. Raymond, MD, L. J Ferrara, MD

Blood (2004) 104 (11): 1228.

https://doi.org/10.1182/blood.V104.11.1228.1228

Published: 2004

NARROW

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Amylase-Producing Myeloma Cells Reduced Sensitivity to Dexamethasone and Bortezomib.

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

L-Asparaginase Monotherapy in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of A Phase II Study.

Phase I Study of Clofarabine (JC0707) in Adult Japanese Patients with Acute Myeloid Leukemia (AML)

Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Keratinocyte Growth Factor Factor (Palifermin) in Combination with Tacrolimus and Methotrexate for the Prevention of Acute Graft-Vs-Host Disease (aGVHD) in Patients at High Risk of Agvhd.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only